NCT07169682

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis: an Observational Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 66 (actual)
• Sponsor: National and Kapodistrian University of Athens · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis. This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL17 inhibitor or an IL23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).

Conditions

• Psoriasis
• Cardiovascular Disease
• Atherosclerosis

Interventions

Type	Name	Description
DRUG	interleukin 17 inhibitor	52 weeks
DRUG	interleukin-23 inhibitor	52 weeks
DRUG	conventional systemic agent or apremilast	52 weeks

Timeline

• Start date: 2021-09-01
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2025-09-12
• Last updated: 2025-09-12

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study